The Bayesian Modeling of Covariates for Population Pharmacokinetic Models
群体药代动力学模型中协变量的贝叶斯建模AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要聚焦药代动力学与剂量建模,个体间变异本身不足以确定所列经济计量细分。
群体药代动力学模型中协变量的贝叶斯建模AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Pharmacokinetic (PK) models describe how the concentrations of a drug and its metabolite vary with time. Population PK models identify and quantify sources of between-individual variability in observed concentrations. Crucial to this aim is the identification of those covariates (i.e., individual-specific characteristics) responsible for explaining the variability. In this article we discuss how covariate modeling can be carried out for population PK models. We argue that the importance of a particular covariate can be discussed only with reference to the specific use for which the model is intended. Covariate modeling is important in population PK studies as it aids in determining dosage recommendations for specific covariate-defined populations. We describe a Bayesian predictive procedure that places covariate modeling in the context of dosage determination. In problems such as these it is crucial to incorporate relevant prior information. For covariate selection we extend the approach of George and McCulloch. The approaches utilize Markov chain Monte Carlo techniques. The methods are illustrated using population PK data from a study of the antibiotic vancomycin in babies. These data are sparse, with just 180 concentrations from 37 babies. Eight covariates are available, from which we construct a covariate model.